The debate between NMN (Nicotinamide Mononucleotide) and NR (Nicotinamide Riboside) as the optimal NAD+ precursor has been central to the longevity supplementation space. Both molecules serve as precursors to NAD+, but they enter the biosynthetic pathway at different points.
NR is converted to NMN by the enzyme NRK (Nicotinamide Riboside Kinase), and NMN is then converted to NAD+ by NMNAT enzymes. This means NMN is one step closer to NAD+ in the biosynthetic pathway, potentially offering a more direct route to NAD+ elevation.
A significant development came with the discovery of the Slc12a8 transporter by Imai et al. (2019), which demonstrated that NMN can be directly transported into cells in the gut, suggesting a specific cellular uptake mechanism that NR does not share.
In terms of stability, NR has historically been considered the more stable of the two in oral supplement form, and later NMN formulation work has addressed many of those concerns.
CELYFE takes a different route entirely: rather than relying on a precursor and the enzymatic conversion steps above, the NAD+ Precision Pen supplies NAD+ itself, the coenzyme, pre-mixed in a sealed research cartridge - so the compound under study is NAD+ rather than a molecule that depends on NRK and NMNAT conversion. This is why the Celyfe compound library is organised around the coenzyme rather than around a precursor.
Regardless of precursor, the research question is the same: what happens to NAD+-dependent pathways when NAD+ availability changes. Which molecule a study uses depends on the pathway step being examined, the format the laboratory can handle and the stability the experimental design needs.
This article is an editorial piece and is provided for informational purposes only. It is not medical advice. Celyfe pens are supplied strictly for in-vitro laboratory research.